Up-regulation of MMP-2 and MMP-9 leads to degradation of type IV collagen during skeletal muscle reperfusion injury; protection by the MMP inhibitor, doxycycline

European Journal of Vascular and Endovascular Surgery

Volumn 23, Issue 3, 2002, Pages 260-269

  Roach, D M ^a   Fitridge, R A ^a   Laws, P E ^a   Millard, S H ^a   Varelias, A ^a   Cowled, P A ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Collagen degradation; Doxycydine; Ischaemia; Matrix metalloproteinases; Reperfusion

Indexed keywords

COLLAGEN TYPE 4; DOXYCYCLINE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; COLLAGEN DEGRADATION; CONTROLLED STUDY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MUSCLE ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SKELETAL MUSCLE; STATISTICAL ANALYSIS; TISSUE INJURY; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; INJURY; KIDNEY; LUNG; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULARIZATION;

ANIMALS; ANTI-BACTERIAL AGENTS; COLLAGEN TYPE IV; DISEASE MODELS, ANIMAL; DOXYCYCLINE; KIDNEY; LUNG; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MUSCLE, SKELETAL; RATS; REPERFUSION INJURY; UP-REGULATION;

EID: 0036518135     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1053/ejvs.2002.1598     Document Type: Article

References (42)

1. KYRIAKIDES C, AUSTEN W, WANG Y et al. Skeletal muscle reperfusion injury is mediated by neutrophils and the complement membrane attack complex. Am J Physiol 1999; 277: C1263-C1268.
2. WONG MS, LARA TM, KOBZIK L et al. Hindlimb ischemia-reperfusion increases complement deposition and glycolysis. J Surg Res 1999; 85: 130-135.
3. GRISOTTO PC, DOS SANTOS AC, COUTINHO-NETTO J, CHERRI J, PICCINATO CE. Indicators of oxidative injury and alterations of the cell membrane in the skeletal muscle of rats submitted to ischemia and reperfusion. J Surg Res 2000; 92: 1-6.
4. SADASIVAN KK, CARDEN DL, MOORE MB, KORTHUIS RJ. Neutrophil mediated microvascular injury in acute, experimental compartment syndrome. Clin Orthop 1997; 17: 206-215.
5. TOTH A, IVANICS T, RUTTNER Z et al. Quantitative assessment of [Ca2+]i levels in rat skeletal muscle in vivo. Am J Physiol 1998; 275: H1652-H1662.
6. SEEKAMP A, MULLIGAN MS, TILL GO, WARD PA. Requirements for neutrophil products and L-arginine in ischemia-reperfusion injury. Am J Pathol 1993; 142: 1217-1226.
7. SCHLAG MG, HARRIS KA, POTTER RF. Role of leukocyte accumulation and oxygen radicals in ischemia-reperfusion-induced injury in skeletal muscle. Am J Physiol Heart Circ Physiol 2001; 280: H1716-H1721.
8. COWLED PA, LEONARDOS L, MILLARD SH, FITRIDGE RA. Apoptotic cell death makes a minor contribution to reperfusion injury in skeletal muscle in the rat. Eur J Vasc Endovasc Surg 2001; 21: 28-34. doi 10.1053/ejvs 1200.1209.
9. NAGASE H, WOESSNER JF. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-21494.
10. HAMANN GF, OKADA Y, FITRIDGE R, DEL ZOPPO GJ. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 1995; 26: 2120-2126.
11. ROSENBERG GA, NAVRATIL M, BARONE F, FEUERSTEIN G. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 1996; 16: 360-366.
12. GASCHE Y, FUJIMURA M, MORITA-FUJIMURA Y et al. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab 1999; 19: 1020-1028.
13. FUJIMURA M, GASCHE Y, MORITA-FUJIMURA Y et al. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 1999; 842: 92-100.
14. ROMANIC AM, WHITE RF, ARLETH AJ, OHLSTEIN EH, BARONE FC. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998; 29: 1020-1030.
15. CLARK WM, LESSOV N, LAUTEN JD, HAZEL K. Doxycycline treatment reduces ischemic brain damage in transient middle cerebral artery occlusion in the rat. J Mol Neurosci 1997; 9: 103-108.
16. PORTER KE, THOMPSON MM, LOFTUS IM et al. Production and inhibition of the gelatinolytic matrix metalloproteinases in a human model of vein graft stenosis. Eur J Vasc Endovasc Surg 1999; 17: 404-412.
17. CARTER WO, BULL C, BORTOLON E et al. A murine skeletal muscle ischemia-reperfusion injury model: differential pathology in BALB/c and DBA/2N mice. J Appl Physiol 1998; 85: 1676-1683.
18. HANEMAAIJER R, VISSER H, KOOLWIJK P et al. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Dent Res 1998; 12: 114-118.
19. SALO T, LIOTTA LA, TRYGGVASON K. Purification and characterization of a murine basement membrane collagen-degrading enzyme secreted by metastatic tumor cells. J Biol Chem 1983; 258: 3058-3063.
20. LYONS JG, BIRKEDAL-HANSEN B, MOORE WG, O'GRADY RL, BIRKEDAL-HANSEN H. Characteristics of a 95-kDa matrix metalloproteinase produced by mammary carcinoma cells. Biochemistry 1991; 30: 1449-1456.
21. MURPHY G, COCKETT MI, WARD RV, DOCHERTY AJ. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 1991; 277: 277-279.
22. MOREL F, BERTHIER S, GUILLOT M et al. Human neutrophil gelatinase is a collagenase type IV. Biochem Biophys Res Commun 1993; 191: 269-274.
23. COLLIER IE, WILHELM SM, EISEN AZ et al. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 1988; 263: 6579-6587.
24. CHEUNG PY, SAWICKI G, WOZNIAK M et al. Matrix metal-loproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000; 101: 1833-1839.
25. STRONGIN AY, COLLIER IE, KRASNOV PA et al. Human 92 kDa type IV collagenase: functional analysis of fibronectin and carboxyl-end domains. Kidney Int 1993; 43: 158-162.
26. OKADA Y, GONOJI Y, NAKA K et al. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem 1992; 267: 21712-21719.
27. ROSENBERG GA, CUNNINGHAM LA, WALLACE J et al. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res 2001; 893: 104-112.
28. FRISDAL E, TEIGER E, LEFAUCHEUR JP et al. Increased expression of gelatinases and alteration of basement membrane in rat soleus muscle following femoral artery ligation. Neuropathol Appl Neurobiol 2000; 26: 11-21.
29. Lu L, GUNJA-SMITH Z, WOESSNER JF et al. Matrix metallo-proteinases and collagen ultrastructure in moderate myocardial ischemia and reperfusion in vivo. Am J Physiol Heart Circ Physiol 2000; 279: H601-H609.
30. DANIELSEN CC, WIGGERS H, ANDERSEN HR. Increased amounts of collagenase and gelatinase in porcine myocardium following ischemia and reperfusion. J Mol Cell Cardiol 1998; 30: 1431-1442.
31. JAIN S, BICKNELL GR, NICHOLSON ML. Molecular changes in extracellular matrix turnover after renal ischaemia-reperfusion injury. Br J Surg 2000; 87: 1188-1192.
32. YAO PM, DELCLAUX C, D'ORTHO MP et al. Cell-matrix interactions modulate 92-kD gelatinase expression by human bronchial epithelial cells. Am J Respir Cell Mol Biol 1998; 18: 813-822.
33. GIBBS DF, WARNER RL, WEISS SJ, JOHNSON KJ, VARANI J. Characterization of matrix metalloproteinases produced by rat alveolar macrophages. Am J Respir Cell Mol Biol 1999; 20: 1136-1144.
34. SHAPIRO SD, SENIOR RM. Matrix metalloproteinases. Matrix degradation and more. Am J Respir Cell Mol Biol 1999; 20: 1100-1102.
35. YANO M, OMOTO Y, YAMAKAWA Y et al. Increased matrix metalloproteinase 9 activity and mRNA expression in lung ischemia-reperfusion injury. J Heart Lung Transplant 2001; 20: 679-686.
36. HIBBS MS. Expression of 92kDa phagocyte gelatinase by inflammatory and connective tissue cells. Matrix Suppl 1992; 1: 51-57.
37. GUERIN CW, HOLLAND PC. Synthesis and secretion of matrix-degrading metalloproteases by human skeletal muscle satellite cells. Dev Dyn 1995; 202: 91-99.
38. BIAN J, SUN Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 1997; 17: 6330-6338.
39. LI Y, CHOPP M, ZHANG ZG, ZALOGA C, NIEWENHUIS L, GAUTAM S. p53-immunoreactive protein and p53 mRNA expression after transient middle cerebral artery occlusion in rats. Stroke 1994; 25: 849-855.
40. WILHELM SM, COLLIER IE, KRONBERGER A et al. Human skin fibroblast stromelysin: structure, glycosylation, substrate specificity, and differential expression in normal and tumorigenic cells. Proc Natl Acad Sci USA 1987; 84: 6725-6729.
41. OGATA Y, ENGHILD JJ, NAGASE H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 1992; 267: 3581-3584.
42. STRONGIN AY, COLLIER I, BANNIKOV G et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995; 270: 5331-5338.